ESMO Symposium on Immuno-Oncology 2016

Oncology Meeting Resources

04 Nov - 06 Nov 2016, Lausanne, Switzerland

ESMO Immuno Oncology 2016 Square

ESMO Symposium on Immuno-Oncology 2016 underlined ESMO’s commitment to educate cancer physicians and researchers in a rapidly evolving area of treating cancer through immunotherapy and offered an update on the latest developments in immuno-oncology in an effort to bring innovative approaches directly to patients.

Abstracts, presentations and webcasts from the ESMO Symposium on Immuno-Oncology 2016 are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful Links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...ns-Attacking-tumour-immune-escape-mechanisms

Date: 05 Nov 2016
Presenter: William Grossman
Resources: Presentation, Webcast

http://oncologypro.esmo.org/Meeting-Resourc...f-the-STING-pathway-to-induce-tumor-immunity

Date: 05 Nov 2016
Presenter: Thomas Dubensky
Resources: Presentation, Webcast

http://oncologypro.esmo.org/Meeting-Resourc...py-Changing-the-treatment-of-advanced-cancer

Date: 05 Nov 2016
Presenter: Robert Andtbacka
Resources: Presentation, Webcast

http://oncologypro.esmo.org/Meeting-Resourc...CT-for-patients-with-advanced-ovarian-cancer

Aim/BackgroundNon-melanoma solid malignancies are frequently infiltrated with T-cells, and the recent successes of adoptive cell transfer immunotherapy (ACT) with tumor infiltrating lymphocytes (TILs)...

Date: 05 Nov 2016
Presenter: Marie Westergaard
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...ociated-TILs-in-resectable-early-stage-NSCLC

Aim/BackgroundSolid tumors have been shown to evade host antitumor immunity through upregulation of the immune checkpoint PD-1/PD-L1 pathway. However, CD47, an antiphagocytic ligand expressed on tumor...

Date: 05 Nov 2016
Presenter: Sean Hall
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...Tapping-CD4-T-cells-for-cancer-immunotherapy

Aim/BackgroundT-cell based immunotherapy is an attractive treatment for advanced cancer. Whereas cellular immune responses against tumour have typically been attributed to CD8 T cells, CD4 T cells play...

Date: 05 Nov 2016
Presenter: Else Marit Inderberg
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...ckade-by-combination-with-oncolytic-vaccines

Aim/BackgroundT-lymphocytes are at the center of anti-cancer strategies, however, their activation is not sufficient as immunosuppressive pathways limit their efficacy.

Date: 05 Nov 2016
Presenter: Cristian Capasso
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...otherapy-for-enabling-dendritic-cell-therapy

Aim/BackgroundVaccination with dendritic cells (DCs), the most potent professional antigen presenting cells in the body, is a promising approach in cancer immunotherapy.

Date: 05 Nov 2016
Presenter: Suvi Parviainen
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...m-cells-and-mononuclear-cells-Cancer-vaccine

Aim/BackgroundActive immunotherapy provides better recognition of tumor-related antigens by immune systems of patients, enhanced immune system and elimination of malignant cells.

Date: 05 Nov 2016
Presenter: Ali Unal
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc.../PD-1-and-PD-L1-expression-in-ovarian-cancer

Aim/BackgroundCheck point molecules such as programmed cell death protein (PD-1) and its ligand PD-L1 have emerged as potential targets in cancer immunotherapy as antibodies against these molecules can...

Date: 05 Nov 2016
Presenter: Verena Wieser
Resources: Abstract